Top ▲

Follicular lymphoma

Disease ID:1228
Name:Follicular lymphoma
Associated with:0 target
1 immuno-relevant ligand
An indolent non-Hodgkin lymphoma.
Database Links
Disease Ontology: DOID:0050873


No target related data available for Follicular lymphoma


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.
Clinical Use: Initially approved to treat chronic lymphocytic leukemia (CLL) in combination with chemotherapy in patients who have received no prior therapy. In November 2012, this antibody was authorised as an orphan drug by the EMA for the treatment of CLL. Full EMA approval for CLL was granted in July 2014.
In February 2016, the US FDA expanded approval to include treatment of patients with follicular lymphoma (FL) who have relapsed after, or are refractory to, a -containing regimen. This new approval is for a combination therapy of obinutuzumab with , followed by obinutuzumab monotherapy.
In September 2019 the FDA granted Breakthrough Therapy Designation as a treatment for lupus nephritis, a condition for which there is no currently FDA-approved drug. Results from Phase 2 trial NCT02550652 (NOBILITY study) led to this designation. Obinutuzumab (plus standard of care) demonstrated enhanced efficacy compared to placebo plus standard of care in achieving complete renal response (results to be published) [1]. | View clinical data
Bioactivity Comments: In vitro, obinutuzumab induces cell death and antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than the original type I anti-CD20 antibodies and [2]. In vivo, obinutuzumab induces a strong antitumour effect [2].
However, we have been unable to find affinity data for this antibody from any open access source. | View biological activity


Show »

1. Genentech Media. FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis. Accessed on 25/09/2019. Modified on 25/09/2019. Genentech,

2. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther, 12 (10): 2031-42. [PMID:23873847]